Wilkinson S, Williamson E, Pokrajac A, et al. - Researchers conducted the study for analyzing the impacts of the three most commonly used drugs for intensification of glycaemic control after metformin monotherapy, sodium glucose co-transporter 2 inhibitors (SGLT2i), dipeptidyl peptidase-4 inhibitors (DPP4i) and sulfonylureas (SU), on measures of cardiovascular and renal risk. Use primary care data from the UK Clinical Practice Research Datalink of 10,631 new users of SU, SGLT2i or DPP4i with metformin. According to this propensity score matched, new-user cohort study, SGLT2is have greater impacts on cardiometabolic risk factors compared with SUs in routine care. Data on routine care replicates closely the effects of diabetes drugs on the physiological variables measured in clinical trials.